Intraosseous vs intravenous access during out of hospital cardiac arrest a Bayesian secondary analysis of a randomised clinical trial summary

What is PACUPod: Critical Care?

PACUPod is your trusted source for evidence-based insights tailored to advanced clinical pharmacists and physicians. Each episode dives into the latest primary literature, covering medication-focused studies across critical care and many more. We break down study designs, highlight key findings, and objectively discuss clinical implications—without the hype—so you stay informed and ready to apply new evidence in practice. Whether you’re preparing for board certification or striving for excellence in patient care, PACUPod helps you make sense of the data, one study at a time.

Britany: Welcome back to PACULit, your go-to podcast for the latest updates in clinical literature. Today, Seth and I will be discussing a fascinating Bayesian secondary analysis comparing intraosseous access versus intravenous access during out-of-hospital cardiac arrest. Seth, this is a critical topic given how essential rapid vascular access is in these emergencies.

Seth: Absolutely, Britany. Out-of-hospital cardiac arrest, or OHCA, affects hundreds of thousands of people worldwide each year, and unfortunately, survival rates remain disappointingly low, hovering around ten percent. The speed and reliability of vascular access for administering life-saving medications like epinephrine can make all the difference in patient outcomes.

Britany: Traditionally, intravenous access has been the standard approach. However, intraosseous access, which involves inserting a needle directly into the bone marrow, has gained popularity because it can be faster and easier to establish, especially when intravenous access is challenging. The big question, though, is whether one method actually improves survival or neurologic outcomes compared to the other.

Seth: That is the key issue. Prior randomized controlled trials have often reported no statistically significant difference between intraosseous and intravenous routes. But frequentist statistics sometimes leave clinicians in a gray zone—“no difference” does not necessarily mean equivalence. This is where Bayesian analysis offers a fresh perspective by quantifying the probability of a clinically meaningful effect.

Britany: Exactly. The study we are discussing today is a Bayesian secondary analysis of the IVIO trial, which enrolled one thousand four hundred seventy-nine adults with non-traumatic out-of-hospital cardiac arrest. The original trial was prospective, randomized, and open-label, but importantly, outcome assessment was blinded to reduce bias.

Seth: The inclusion criteria were straightforward: adults aged eighteen years or older experiencing non-traumatic cardiac arrest, with emergency medical services personnel attempting vascular access. They excluded traumatic arrests and patients who already had vascular access in place prior to EMS arrival.

Britany: In the intervention group, patients received intraosseous access, typically at tibial or humeral sites, while the comparator group received intravenous access through peripheral veins. The primary outcome was sustained return of spontaneous circulation, or ROSC. Secondary outcomes included thirty-day survival and favorable neurologic outcome at thirty days, defined as a Cerebral Performance Category score of one or two.

Seth: What makes this study compelling is the statistical approach. The researchers used Bayesian hierarchical modeling, incorporating informative priors derived from previous meta-analyses. This allowed them to calculate posterior probabilities for clinically meaningful differences, with predefined thresholds such as an absolute risk difference greater than one to two percent.

Britany: That is a key point. Instead of simply stating “no significant difference,” they could say, for example, there is only a one point two percent probability that intraosseous access improves sustained ROSC meaningfully compared to intravenous access. This probabilistic interpretation is more actionable for clinicians making real-time decisions.

Seth: Diving into the results, the Bayesian analysis showed a very low probability of benefit for intraosseous over intravenous access in achieving sustained ROSC—just about one point two percent. Conversely, the chance that intravenous access was superior was even lower, less than zero point one percent. For thirty-day survival, there was roughly a fifty-eight percent chance of no meaningful difference between the two methods.

Britany: Similarly, for favorable neurologic outcomes at thirty days, the probability of no meaningful difference was about fifty-five percent. These findings align with prior meta-analyses, such as the study by Ibrahim and colleagues published in twenty twenty-five, which analyzed over twenty-eight thousand out-of-hospital cardiac arrest patients and found no significant survival or ROSC differences between intraosseous and intravenous access.

Seth: Right, and Kokori’s systematic review from the same year emphasized that while intraosseous access provides rapid vascular entry, it does not confer a survival advantage. This supports the idea that both routes are clinically valid, allowing emergency medical services providers flexibility based on the situation.

Britany: Another meta-analysis by Alsagban and colleagues reinforced comparable safety profiles and outcomes between intraosseous and intravenous routes. Taken together, these studies suggest that the choice of access should be guided by practical considerations such as ease and speed rather than expecting a survival benefit.

Seth: From a clinical standpoint, this means intraosseous access is particularly valuable when intravenous access is difficult or delayed, such as in patients with collapsed veins or obesity. The ability to establish access quickly facilitates timely drug delivery, which is crucial during resuscitation efforts.

Britany: Absolutely. However, it is important to note that this Bayesian analysis was a secondary analysis dependent on the parent trial data. While robust, it still has limitations, including limited data on pediatric patients and traumatic arrests. Additionally, some clinicians may be less familiar with Bayesian statistics, which can affect interpretation.

Seth: That is true. Nevertheless, sensitivity analyses confirmed the robustness of the findings, and the use of informative priors from meta-analyses strengthens the conclusions. The study also highlights the need for ongoing emergency medical services training to maintain proficiency in both intraosseous and intravenous techniques.

Britany: Speaking of training, one clinical pearl is that intraosseous access, while generally safe, requires attention to proper needle placement and monitoring for complications such as extravasation or compartment syndrome. Drug pharmacokinetics can differ slightly with intraosseous administration, but epinephrine and other resuscitation drugs have been shown to be effectively delivered via this route.

Seth: Good point. Also, drug interactions remain similar regardless of access route, but clinicians should be mindful that intraosseous access might have slightly different absorption kinetics, especially for larger molecules or lipid-soluble drugs. This is an area where further pharmacokinetic studies could be valuable.

Britany: Another interesting aspect is the patient population. The study focused on adults with non-traumatic cardiac arrest, so we cannot generalize these findings to pediatric patients or traumatic arrests. Those populations may have different vascular access challenges and outcomes.

Seth: Exactly. Future research could explore whether certain subgroups, such as patients with initial shockable rhythms or varying emergency medical services response times, might benefit more from one access route. Also, the optimal approach after a failed initial access attempt remains unclear.

Britany: And long-term functional outcomes beyond thirty days, including quality of life and cognitive function, are not extensively reported. These are critical endpoints for survivors and should be prioritized in future trials.

Seth: To summarize, this Bayesian secondary analysis provides a nuanced interpretation of the IVIO trial data, showing a very low probability of clinically meaningful differences between intraosseous and intravenous access during out-of-hospital cardiac arrest. This reinforces clinical equipoise and supports flexibility in vascular access strategies.

Britany: Exactly, Seth. For clinicians, the takeaway is that both intraosseous and intravenous access are effective and valid during resuscitation. Intraosseous access should be considered especially when intravenous access is challenging, enabling faster drug delivery without compromising outcomes.

Seth: Maintaining emergency medical services training and protocols that support proficiency in both techniques is essential. This ensures that providers can adapt to the clinical scenario and optimize patient care.

Britany: Thanks for this insightful discussion, Seth. And thank you to our listeners for joining us on PACULit. Stay tuned for more updates on cutting-edge clinical research to keep your practice evidence-based and patient-centered.

Seth: Thanks, Britany. Looking forward to our next episode, where we will explore emerging therapies in critical care pharmacology. Until then, keep questioning and stay curious.

Britany: Absolutely. Take care, everyone!